$1.66 Billion is the total value of Sofinnova Investments, Inc.'s 64 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 55.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NTRA | Natera | $314,831,000 | +2.0% | 3,100,560 | 0.0% | 18.93% | +3.0% | |
| KRTX | Karuna Therapeutics, Inc. | $234,742,000 | +18.3% | 1,952,441 | 0.0% | 14.11% | +19.5% | |
| BOLT | New | Bolt Biotherapeutics, Inc. | $90,649,000 | – | 2,754,437 | +100.0% | 5.45% | – |
| ASND | Sell | Ascendis Pharma A/Sadr | $67,265,000 | -63.7% | 521,923 | -53.0% | 4.04% | -63.3% |
| YMAB | Y-mAbs Therapeutics, Inc | $66,355,000 | -38.9% | 2,194,278 | 0.0% | 3.99% | -38.3% | |
| AZN | Buy | AstraZeneca PLCadr | $51,497,000 | +22.3% | 1,035,732 | +22.9% | 3.10% | +23.4% |
| New | Health Care Select Sector SPDRput | $46,696,000 | – | 400,000 | +100.0% | 2.81% | – | |
| CMPI | Checkmate Pharmaceuticals Inc | $43,785,000 | -16.8% | 3,606,707 | 0.0% | 2.63% | -16.0% | |
| JAZZ | Buy | Jazz Pharmaceuticals PLC | $42,067,000 | +19.7% | 255,928 | +20.2% | 2.53% | +20.9% |
| INZY | Inozyme Pharma, Inc. | $40,160,000 | -4.1% | 2,028,308 | 0.0% | 2.41% | -3.1% | |
| UTHR | Sell | United Therapeutics Corp | $35,972,000 | -31.9% | 215,054 | -38.2% | 2.16% | -31.2% |
| LLY | Buy | Eli Lilly and Co | $33,721,000 | +441.1% | 180,501 | +389.0% | 2.03% | +446.4% |
| NCNA | Nucana Biomed Ltdadr | $27,944,000 | +11.1% | 5,599,999 | 0.0% | 1.68% | +12.2% | |
| MRUS | Merus N.V. | $27,388,000 | +19.2% | 1,311,039 | 0.0% | 1.65% | +20.3% | |
| GRTX | Galera Therapeutics, Inc | $27,198,000 | -13.8% | 3,083,712 | 0.0% | 1.64% | -12.9% | |
| NXTC | New | Nextcure, Inc | $26,745,000 | – | 2,671,856 | +100.0% | 1.61% | – |
| ALGN | New | Align Technology Inc | $24,640,000 | – | 45,500 | +100.0% | 1.48% | – |
| XLRN | Buy | Acceleron Pharma Inc | $24,212,000 | +415.8% | 178,538 | +386.6% | 1.46% | +421.9% |
| RETA | Buy | Reata Pharmaceuticals Inc | $23,780,000 | +29.2% | 238,520 | +60.1% | 1.43% | +30.5% |
| MRTX | New | Mirati Therapeutics Inc | $23,645,000 | – | 138,030 | +100.0% | 1.42% | – |
| ITCI | Sell | Intra-Cellular Therapies Inc | $22,224,000 | -17.6% | 655,001 | -22.8% | 1.34% | -16.8% |
| PTCT | Buy | PTC Therapeutics Inc | $22,105,000 | +14.4% | 466,840 | +47.5% | 1.33% | +15.6% |
| INSM | Buy | Insmed Inc | $21,081,000 | +104.5% | 618,950 | +99.9% | 1.27% | +106.4% |
| AKUS | Akouos, Inc | $21,014,000 | -30.1% | 1,515,074 | 0.0% | 1.26% | -29.4% | |
| New | Gilead Sciences Inccall | $19,389,000 | – | 300,000 | +100.0% | 1.17% | – | |
| EXEL | New | Exelixis Inc | $18,957,000 | – | 839,181 | +100.0% | 1.14% | – |
| PTGX | New | Protagonist Therapeutics Inc | $16,962,000 | – | 654,900 | +100.0% | 1.02% | – |
| OBSV | ObsEva SA | $15,436,000 | +56.3% | 4,749,623 | 0.0% | 0.93% | +57.8% | |
| QURE | New | Uniqure NV | $14,390,000 | – | 427,122 | +100.0% | 0.86% | – |
| RGNX | Buy | Regenxbio Inc | $12,339,000 | +0.3% | 361,735 | +33.4% | 0.74% | +1.4% |
| HZNP | Sell | Horizon Therapeutics PLC | $12,333,000 | -21.0% | 133,997 | -37.2% | 0.74% | -20.2% |
| New | Nucana Biomed Ltdordinary shares | $11,976,000 | – | 2,400,000 | +100.0% | 0.72% | – | |
| VRTX | New | Vertex Pharmaceuticals Inc | $9,820,000 | – | 45,700 | +100.0% | 0.59% | – |
| DXCM | New | Dexcom Inc | $9,704,000 | – | 27,000 | +100.0% | 0.58% | – |
| AMGN | Sell | Amgen Inc | $9,671,000 | -74.5% | 38,868 | -76.4% | 0.58% | -74.2% |
| AGEN | New | Agenus Inc | $9,461,000 | – | 3,478,201 | +100.0% | 0.57% | – |
| MIRM | Buy | Mirum Pharmaceuticals Inc | $9,442,000 | +18.9% | 476,401 | +4.7% | 0.57% | +20.1% |
| ATHA | Athira Pharma, Inc. | $9,369,000 | -46.3% | 509,168 | 0.0% | 0.56% | -45.8% | |
| CCXI | Buy | ChemoCentryx Inc | $9,223,000 | +31.6% | 179,999 | +59.0% | 0.55% | +32.9% |
| CYTK | Sell | Cytokinetics Inc | $9,065,000 | -14.2% | 389,720 | -23.3% | 0.54% | -13.4% |
| New | ChemoCentryx Incput | $7,686,000 | – | 150,000 | +100.0% | 0.46% | – | |
| TCRR | Buy | TCR2 Therapeutics Inc | $7,434,000 | -28.0% | 336,682 | +0.9% | 0.45% | -27.2% |
| AMRN | Amarin Corpadr | $7,269,000 | +27.0% | 1,170,584 | 0.0% | 0.44% | +28.2% | |
| SNDX | Sell | Syndax Pharmaceuticals Inc | $6,678,000 | -19.5% | 298,644 | -19.9% | 0.40% | -18.8% |
| ARNA | Sell | Arena Pharmaceuticals Inc | $6,346,000 | -31.9% | 91,448 | -24.7% | 0.38% | -31.2% |
| CHRS | Coherus BioSciences | $6,349,000 | -15.9% | 434,555 | 0.0% | 0.38% | -15.1% | |
| Buy | Marinus Pharmaceuticals Inc | $5,733,000 | +71.5% | 370,351 | +35.2% | 0.34% | +73.4% | |
| JNCE | Sell | Jounce Therapeutics Inc | $5,256,000 | -18.9% | 511,822 | -44.7% | 0.32% | -18.1% |
| PODD | New | Insulet Corp | $4,566,000 | – | 17,500 | +100.0% | 0.27% | – |
| FATE | Buy | Fate Therapeutics Inc | $4,518,000 | +268.2% | 54,795 | +306.0% | 0.27% | +272.6% |
| REPL | Buy | Replimune Group Inc | $4,339,000 | +468.7% | 142,209 | +611.0% | 0.26% | +480.0% |
| IMTX | Buy | Immatics NV | $4,317,000 | +43.1% | 385,099 | +37.8% | 0.26% | +44.4% |
| ALGS | Sell | Aligos Therapeutics Inc | $4,219,000 | -20.1% | 185,532 | -2.9% | 0.25% | -19.1% |
| Sell | Aptose Biosciences Inc | $4,164,000 | -3.1% | 696,928 | -29.0% | 0.25% | -2.3% | |
| New | Heron Therapeutics Inccall | $4,053,000 | – | 250,000 | +100.0% | 0.24% | – | |
| BCRX | Sell | BioCryst Pharmaceuticals Inc | $3,852,000 | -54.0% | 378,774 | -66.3% | 0.23% | -53.4% |
| SVRA | New | Savara Inc | $3,614,000 | – | 1,737,450 | +100.0% | 0.22% | – |
| PBYI | Sell | Puma Biotechnology Inc | $3,353,000 | -48.1% | 344,917 | -45.2% | 0.20% | -47.5% |
| OTIC | Sell | Otonomy Inc | $3,191,000 | -81.2% | 1,251,256 | -52.3% | 0.19% | -81.0% |
| KURA | Sell | Kura Oncology Inc | $2,351,000 | -40.3% | 83,164 | -31.1% | 0.14% | -40.0% |
| MGNX | Sell | MacroGenics Inc | $2,331,000 | -77.8% | 73,201 | -84.0% | 0.14% | -77.6% |
| SYBX | Synlogic Inc. | $2,058,000 | +65.7% | 574,972 | 0.0% | 0.12% | +67.6% | |
| CALA | Buy | Calithera Biosciences Inc | $1,833,000 | -25.4% | 757,533 | +51.4% | 0.11% | -24.7% |
| PDSB | PDS Biotechnology Corporation | $649,000 | +112.8% | 142,635 | 0.0% | 0.04% | +116.7% | |
| BCAB | Exit | Bioatla Inc | $0 | – | -3,000 | -100.0% | -0.01% | – |
| LQDA | Exit | Liquidia Corp | $0 | – | -147,744 | -100.0% | -0.03% | – |
| CALA | Exit | Calithera Biosciences Inccall | $0 | – | -175,000 | -100.0% | -0.05% | – |
| KDMN | Exit | Kadmon Holdings Inc | $0 | – | -228,893 | -100.0% | -0.06% | – |
| ZGNX | Exit | Zogenix Inc | $0 | – | -89,579 | -100.0% | -0.11% | – |
| CALA | Exit | Calithera Biosciences Incput | $0 | – | -400,000 | -100.0% | -0.12% | – |
| TGTX | Exit | TG Therapeutics Inc | $0 | – | -65,474 | -100.0% | -0.20% | – |
| IGMS | Exit | IGM Biosciences Inc | $0 | – | -45,131 | -100.0% | -0.24% | – |
| IOVA | Exit | Iovance Biotherapeutics Incput | $0 | – | -100,000 | -100.0% | -0.28% | – |
| RCUS | Exit | Arcus Biosciences Inc | $0 | – | -186,278 | -100.0% | -0.29% | – |
| ACAD | Exit | ACADIA Pharmaceuticals Inc | $0 | – | -164,625 | -100.0% | -0.52% | – |
| SRPT | Exit | Sarepta Therapeutics Inc | $0 | – | -51,848 | -100.0% | -0.53% | – |
| Exit | Nucana Biomed Ltdordinary shares | $0 | – | -2,400,000 | -100.0% | -0.64% | – | |
| GWPH | Exit | GW Pharmaceuticals PLCadr | $0 | – | -100,762 | -100.0% | -0.69% | – |
| ACRS | Exit | Aclaris Therapeutics | $0 | – | -1,911,573 | -100.0% | -0.74% | – |
| BMRN | Exit | Biomarin Pharmaceutical Inc | $0 | – | -164,545 | -100.0% | -0.86% | – |
| Exit | Protagonist Therapeutics Inc | $0 | – | -724,904 | -100.0% | -0.87% | – | |
| IWM | Exit | iShares Russell 2000 ETFput | $0 | – | -130,000 | -100.0% | -1.52% | – |
| Exit | Nextcure, Inc | $0 | – | -2,671,856 | -100.0% | -1.73% | – | |
| ABBV | Exit | Abbvie Inc | $0 | – | -293,596 | -100.0% | -1.87% | – |
| XLV | Exit | Health Care Select Sector SPDRput | $0 | – | -300,000 | -100.0% | -2.03% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Natera, Inc. | 23 | Q3 2023 | 20.5% |
| Ascendis Pharma A/S | 23 | Q3 2023 | 27.9% |
| NuCana plc | 23 | Q3 2023 | 15.2% |
| Synlogic Inc. (fmrly Mirna) | 22 | Q2 2023 | 0.9% |
| Y-mAbs Therapeutics, Inc. | 21 | Q3 2023 | 6.5% |
| ObsEva SA | 20 | Q4 2022 | 11.0% |
| Nucana PLC | 19 | Q3 2023 | 9.7% |
| SYNDAX PHARMACEUTICALS INC | 19 | Q3 2023 | 2.2% |
| PDS Biotechnology Corporation | 19 | Q3 2023 | 0.1% |
| Karuna Therapeutics, Inc. | 18 | Q3 2023 | 27.1% |
View Sofinnova Investments, Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| OTONOMY, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Sofinnova Investments, Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
View Sofinnova Investments, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.